Ozempic Dose Chart: Titration and Maintenance

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide dosing and protocol hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

The Dose Step That Breaks People

Marissa, 43, in Phoenix, had sailed through her first eight weeks on compounded semaglutide. The 0.25 mg felt like nothing. The bump to 0.5 mg gave her some mild queasiness on injection day, gone by dinner. Then her clinician moved her to 1.0 mg, and she spent two days on the couch with nausea so heavy she couldn't look at food. "I almost quit the whole thing," she told her prescriber at her follow-up. "I figured this was what it was going to feel like forever." Her clinician held her at 0.5 mg for an extra four weeks, then tried the jump again. Second time around, she barely noticed it.

Marissa's story is ordinary. It's the most ordinary thing about semaglutide therapy: the titration schedule matters more than almost any other variable, and skipping or rushing steps punishes you for it. That's what an Ozempic dose chart is really trying to communicate, even though most of the ones floating around the internet present it as a flat table of numbers with no context.

This guide is part of the broader Compounded Semaglutide Dosing and Protocols cluster, which feeds into the compounded semaglutide pillar guide.

The Standard Titration, Explained Simply

Two dose charts circulate in clinical practice, and they serve different populations. Understanding which one applies to you is the first job.

The Wegovy (weight management) schedule, used in the STEP-1 trial, has five steps:

Weeks 1 through 4: 0.25 mg once weekly
Weeks 5 through 8: 0.5 mg
Weeks 9 through 12: 1.0 mg
Weeks 13 through 16: 1.7 mg
Week 17 onward: 2.4 mg (maintenance)

The Ozempic (diabetes) schedule is shorter and tops out lower:

Weeks 1 through 4: 0.25 mg
Then 0.5 mg, then 1.0 mg, with 2.0 mg available for patients who need additional glycemic control

Ozempic is not labeled for chronic weight management. When a clinician uses Ozempic for weight-related goals, the reasoning usually involves comorbid diabetes, insurance routing, or supply availability. The pharmacy-level supply situation in 2026 is more stable than the chaos of 2023 and 2024, but it still shifts.

Here's the thing about both charts: the 0.25 mg step is not a treatment dose. It is a tolerability dose. Your body is learning to live with slower gastric emptying, altered satiety signals, and a GLP-1 receptor agonist that has a half-life long enough to keep working all week. Skipping this step is like removing the first rung of a ladder and wondering why you pulled a muscle climbing up.

What Compounded Semaglutide Programs Do Differently

Compounded semaglutide is not FDA-approved. Compounding pharmacies prepare it for individual patients under a clinician's prescription, using the same active molecule found in Wegovy and Ozempic. The clinical evidence base for semaglutide as a molecule comes from the branded product trials. Compounded preparations have not been independently tested in randomized trials at the same scale.

In practice, most compounded semaglutide programs model their titration on the Wegovy schedule above. But they're not locked into the discrete dose levels of the pre-filled pen. A clinician working with a compounding pharmacy can prescribe 0.75 mg, or 1.25 mg, or any increment that makes clinical sense for a particular patient. That flexibility is genuinely useful for people like Marissa who tolerate one step but crash at the next. It lets a prescriber split the difference rather than choosing between "stay" and "full jump."

The dose chart you receive from a compounded program will list milligrams rather than pen clicks. Read it carefully. If something looks off, call the pharmacy or your prescriber. This is not an area where approximation is acceptable.

Knowing When a Dose Needs to Change

Three patterns reliably trigger a dose adjustment in clinical practice:

GI symptoms that don't resolve. Some nausea in the first week after a dose increase is expected. Nausea that persists beyond seven to ten days, or that escalates into vomiting or diarrhea severe enough to affect hydration, usually means holding or stepping back. The distinction between "adjustment discomfort" and "this dose is too high" is one a clinician should make, not a patient forum.

Weight loss that's too fast. Counterintuitive, but real. When a patient is losing more than 1.5 to 2 percent of body weight per week consistently, the rate is usually unsustainable and raises concerns about lean mass loss. Faster is not better here.

A stalled response at maintenance. After several months at the target dose, some patients plateau. The boring truth is that a plateau often calls for a lifestyle audit (protein intake, resistance training, sleep) rather than a higher dose. Sometimes a different intervention entirely is warranted.

The Trial Evidence Behind These Numbers

The dose chart is not arbitrary. It maps to a specific trial program.

STEP-1 tested 2.4 mg weekly semaglutide against placebo over 68 weeks. Mean weight loss in the active arm was 14.9 percent from baseline. STEP-3 added a structured lifestyle intervention (intensive behavioral therapy, meal replacements during an initial low-calorie phase) and produced even greater mean weight loss. The reading is clear: lifestyle effort is additive, not optional.

STEP-4 documented what happens when the drug stops. Patients switched from semaglutide to placebo at week 20 showed partial weight regain over the next 48 weeks. This is not a failure of the medication. It's the chronic biology of weight regulation doing exactly what it does with any chronic condition when treatment is removed. Think of it like blood pressure medication: the pill doesn't cure hypertension, it manages it. Stop the pill, the pressure comes back.

SUSTAIN-6 and LEADER anchor the cardiovascular safety profile for the GLP-1 class. SELECT, completed in 2023, reported a 20 percent relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with established cardiovascular disease and overweight or obesity without diabetes.

How to Actually Read a Dose Chart

When you see an Ozempic dose chart, either in a prescribing leaflet, a clinic handout, or on a screen, you're looking at four numbers: 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg. Each step is held for a minimum of four weeks. The 0.5 mg and 1.0 mg doses are the most common maintenance doses for blood sugar control. The 2.0 mg dose exists for patients who need additional glycemic effect.

For patients whose prescriber has chosen Ozempic over Wegovy for weight-related goals, the chart functions similarly but with a lower ceiling. Understanding why your clinician made that choice (comorbid diabetes, insurance considerations, supply) is worth asking about. You should know.

A few things that trip patients up:

The chart shows minimum hold times. You can stay at a dose longer. You should if tolerability demands it.
Moving backward is not failing. It's adjusting.
The chart doesn't tell you what to eat, how much protein to aim for, or when to start resistance training. Those conversations happen with your clinician separately, and they matter as much as the dose.

Four Misconceptions That Keep Coming Up

"Compounded is the same as branded, just cheaper." Same molecule. Different regulatory pathway. Compounding pharmacies operate under a separate framework with different oversight. Compounded preparations are not FDA-approved. This doesn't mean they're dangerous, but it does mean the regulatory protections are structured differently, and patients should understand that distinction.

"Worse side effects mean better results." Trial data from STEP-1 and STEP-3 do not support this. Patients with mild GI symptoms and patients with pronounced nausea both achieved meaningful weight loss. Your tolerance level is not a proxy for how well the drug is working.

"The medication does the work." STEP-3's results, which exceeded STEP-1's, argue otherwise. Semaglutide reduces appetite and changes satiety signaling. What you do with that reduced appetite (the protein you prioritize, the movement you add, the sleep you protect) determines a significant portion of your outcome.

"Stopping the drug puts you back where you started." STEP-4 showed partial regain, not complete rebound. The degree of regain varies by individual and is influenced by what habits were built during the treatment period. "Partial" and "total" are different words for a reason.

The Clinician Relationship Matters More Than the Chart

My genuinely opinionated take: the quality of the clinical relationship behind a semaglutide prescription matters more than the specific program, brand, or even the dose chart itself. A prescriber who responds to your side-effect reports, adjusts timing when something isn't working, and checks in between refills will produce better outcomes than a slick intake form followed by silence. If your program doesn't have a clear mechanism for you to report problems between appointments, that is a red flag.

The dose chart is a tool. It tells you the sequence. It does not tell you what to do when the sequence doesn't fit. That's what a clinician is for.

Practical Notes on Injection Day

Semaglutide is a subcutaneous injection, delivered into the abdomen, upper thigh, or upper arm. Rotate sites week to week. Bring the medication to room temperature for fifteen to twenty minutes before injection. Return it to refrigeration afterward unless the pharmacy specifies a defined room-temperature storage window.

Pick a consistent day and time. Not because the pharmacology demands it (semaglutide's half-life is forgiving), but because routine protects adherence, and consistent timing makes it easier to spot tolerability patterns. If you always inject on Thursday evening and always feel queasy Friday morning, that's useful data. If you inject on random days, that pattern disappears into noise.

The injection itself takes seconds. Patients almost universally say the anticipation was worse than the needle.

Adjacent Reading

Where This Fits

This article is part of the Compounded Semaglutide Dosing and Protocols cluster. For broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

What dose of compounded semaglutide is considered standard?

There is no single "standard" dose. Compounded semaglutide protocols are written by the prescribing clinician and typically informed by the Wegovy escalation schedule from STEP-1: 0.25 mg weekly for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg, with the titration rate adjusted to tolerability. Compounded preparations are not FDA-approved and dosing is not standardized across pharmacies.

How does titration speed affect tolerability?

Slow titration is the single biggest determinant of gastrointestinal tolerability in published semaglutide trials. The STEP-1 protocol used four-week steps specifically to let gastric emptying changes adapt gradually. Clinicians who rush patients through these steps see higher dropout rates.

Can a clinician hold a dose without restarting the whole schedule?

Yes. Holding a current dose for an extra cycle to let side effects settle is a common and appropriate clinical adjustment. It does not require restarting the full titration. A multi-week gap off the medication entirely, however, may warrant stepping back down before resuming.

Is the 0.25 mg dose supposed to cause weight loss?

Not usually. The 0.25 mg dose is a tolerability step, not a therapeutic dose for weight management. Some patients notice mild appetite reduction, but the purpose of this step is to let your GI system adapt before moving to doses where clinical effect begins.

What's the difference between the Ozempic chart and the Wegovy chart?

The Ozempic chart tops out at 2.0 mg and is designed for glycemic control in type 2 diabetes. The Wegovy chart goes to 2.4 mg and includes the 1.7 mg intermediate step. Ozempic is not labeled for weight management. The choice between them depends on clinical indication, insurance coverage, and supply.

Should I adjust my own dose if I feel fine?

No. Dose changes should be made by your prescribing clinician. "Feeling fine" at a given dose is good information to share at your next check-in, but it doesn't mean you should self-escalate. The titration exists for physiological reasons that aren't always perceptible to the patient.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.